Search

Your search keyword '"Masuyama, Hisashi"' showing total 578 results
Start Over Author "Masuyama, Hisashi"
578 results on '"Masuyama, Hisashi"'

2. Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study

Author

Nagao, Shoji, Nishio, Shin, Takehara, Kazuhiro, Sato, Shinya, Satoh, Toyomi, Shimada, Muneaki, Yamaguchi, Satoshi, Tanabe, Hiroshi, Takano, Masashi, Horie, Kouji, Takei, Yuji, Imai, Yuichi, Hibino, Yumi, Hasegawa, Kosei, Takekuma, Munetaka, Nakamura, Kazuto, Takano, Hirokuni, Fujiwara, Keiichi, and Masuyama, Hisashi

Published
2024
Full Text
View/download PDF

18. Effectiveness, reliability, and validity of new Japanese diagnostic criteria for obstetrical disseminated intravascular coagulation (tentative version): A retrospective multicenter study

Author

Morikawa, Mamoru, primary, Takeda, Yoshiharu, additional, Matsunaga, Shigetaka, additional, Makino, Shintaro, additional, Eto, Eriko, additional, Serizawa, Mariko, additional, Nii, Masafumi, additional, Takeda, Jun, additional, Masuyama, Hisashi, additional, and Itakura, Atsuo, additional

Published
2024
Full Text
View/download PDF

26. Association of Regular Cervical Cancer Screening with Socioeconomic, COVID-19 Infection and Vaccine Status Among Japanese Population: Cohort Observational Study

Author

Mitoma,Tomohiro, Maki,Jota, Ooba,Hikaru, Ogawa,Chikako, Masuyama,Hisashi, Tabuchi,Takahiro, Mitoma,Tomohiro, Maki,Jota, Ooba,Hikaru, Ogawa,Chikako, Masuyama,Hisashi, and Tabuchi,Takahiro

Abstract

Tomohiro Mitoma,1 Jota Maki,1 Hikaru Ooba,1 Chikako Ogawa,1 Hisashi Masuyama,1 Takahiro Tabuchi2 1Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan; 2Department of Cancer Control Center, Osaka International Cancer Institute, Osaka, JapanCorrespondence: Jota Maki, Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan, Tel +81-86-235-7320, Fax +81-86-225-9570, Email jotamaki@okayama-u.ac.jpPurpose: Among the Organisation for Economic Co-operation and Development countries, Japan has one of the lowest cervical cancer screening coverages. Cancer screening coverage has worsened due to the coronavirus disease of 2019 (COVID-19) pandemic. This study investigated the relationship between socioeconomic background, COVID-19 infection history and vaccine status, and regular cervical cancer screening (CCS) during the two years of the COVID-19 era in Japan.Patients and Methods: We used data from the Japan COVID-19 and Society Internet Survey, a nationwide, Internet-based, self-report cohort observational study conducted in 2022. The outcome variable was identified by asking whether the participants had undergone CCS within the last two years. Cervical cytology was performed in Japan by brushing the external cervical os. This study used multivariate log-binomial regression models to evaluate inequalities during regular checkups for CCS. Adjusted prevalence ratios (APRs) with 95% confidence intervals (CIs) were estimated to incorporate the socioeconomic background variables.Results: Of the 12,066 participants, 5597 (46.4%) had undergone regular CCS for over two years. The prevalence ratio (PR) of patients who underwent CCS was 0.70 for those in their 20s and 0.78 for those in their 60s, compared to those in their 40s. Socioeconomic inequities were found in the follow

Published
2024

32. Assessing the Efficacy of Simulation-Based Education for Paramedics in Extended Focused Assessment with Sonography for Trauma under Physician Guidance

Author

Ohira, Akiko, primary, Maki, Jota, additional, Ageta, Kohei, additional, Nakato, Hikari, additional, Oba, Hikaru, additional, Mitoma, Tomohiro, additional, Mishima, Sakurako, additional, Tani, Kazumasa, additional, Kirino, Satoe, additional, Eto, Eriko, additional, Nakao, Atsunori, additional, and Masuyama, Hisashi, additional

Published
2023
Full Text
View/download PDF

34. Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy

Author

Suzumori, Nobuhiro, Sekizawa, Akihiko, Ebara, Takeshi, Samura, Osamu, Sasaki, Aiko, Akaishi, Rina, Wada, Seiji, Hamanoue, Haruka, Hirahara, Fumiki, Izumi, Haruna, Sawai, Hideaki, Nakamura, Hiroaki, Yamada, Takahiro, Miura, Kiyonori, Masuzaki, Hideaki, Yamashita, Takahiro, Okai, Takashi, Kamei, Yoshimasa, Namba, Akira, Murotsuki, Jun, Tanemoto, Tomohiro, Fukushima, Akimune, Haino, Kazufumi, Tairaku, Shinya, Matsubara, Keiichi, Maeda, Kazutoshi, Kaji, Takashi, Ogawa, Masanobu, Osada, Hisao, Nishizawa, Haruki, Okamoto, Yoko, Kanagawa, Takeshi, Kakigano, Aiko, Kitagawa, Michihiro, Ogawa, Masaki, Izumi, Shunichiro, Katagiri, Yukiko, Takeshita, Naoki, Kasai, Yasuyo, Naruse, Katsuhiko, Neki, Reiko, Masuyama, Hisashi, Hyodo, Maki, Kawano, Yukie, Ohba, Takashi, Ichizuka, Kiyotake, Nagamatsu, Takeshi, Watanabe, Atsushi, Shirato, Nahoko, Yotsumoto, Junko, Nishiyama, Miyuki, Hirose, Tatsuko, and Sago, Haruhiko

Published
2018
Full Text
View/download PDF

35. Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer

Author

Nakamura, Keiichiro, primary, Matsuoka, Hirofumi, additional, Yorimitsu, Masae, additional, Ogawa, Mariko, additional, Kanemori, Miho, additional, Sueoka, Kotaro, additional, Kozai, Ayumi, additional, Nakamura, Hiroko, additional, Haruma, Tomoko, additional, Shiroyama, Yuko, additional, Hayata, Yuu, additional, Sugii, Hirokazu, additional, Ueda, Akiko, additional, Kurihara, Shuichi, additional, Urayama, Saiko, additional, Shimizu, Miyuki, additional, and Masuyama, Hisashi, additional

Published
2023
Full Text
View/download PDF

38. Pure abscopal effect in a patient with advanced uterine carcinosarcoma

Author

Okamoto, Kazuhiro, primary, Yoshio, Kotaro, additional, Shirakawa, Shinsuke, additional, Irie, Kyohei, additional, Ida, Naoyuki, additional, Matsuoka, Hirofumi, additional, Haraga, Junko, additional, Ogawa, Chikako, additional, Nakamura, Keiichiro, additional, Nagao, Shoji, additional, and Masuyama, Hisashi, additional

Published
2023
Full Text
View/download PDF

41. Investigation of optimal weight gain during pregnancy: A retrospective analysis of the Japanese perinatal registry database.

Author

Takeda, Jun, Morisaki, Naho, Itakura, Atsuo, Aoki, Shigeru, Sago, Haruhiko, Nagamatsu, Takeshi, Masuyama, Hisashi, Matsubara, Shigeki, Umazume, Takeshi, Mitsuda, Nobuaki, Itoh, Hiroaki, and Ikeda, Tomoaki

Subjects
WEIGHT gain in pregnancy, MATERNAL health services, OBESITY, BIBLIOGRAPHIC databases, MATHEMATICAL models, RETROSPECTIVE studies, ACQUISITION of data, OBSTETRICS, SURVEYS, WEIGHT gain, MEDICAL records, QUESTIONNAIRES, THEORY, ADVERSE health care events, PREDICTION models, BODY mass index, PROBABILITY theory, PRECONCEPTION care, PREGNANCY
Abstract

Aim: This study aimed to determine the weight gain during pregnancy that minimizes the predicted probability of various perinatal adverse events according to the pre‐pregnancy body mass index (BMI) and make recommendations for optimal weight gain in Japan. Methods: The Japan Society of Obstetrics and Gynecology perinatal database for 2015–2017 was used. From the 719 723 deliveries included in this database, parturients with underlying diseases or missing data were excluded, and 419 114 deliveries were analyzed. A questionnaire survey was also conducted to weigh each perinatal adverse event. For each of the nine outcomes, a restricted cubic spline model was made to estimate the association between the "expected gestational weight gain at 40 weeks" and the outcome risk. Results: Since the classes of medical facilities were generally the same, weights were assigned according to the mean of the questionnaires rather than by the class of the facility. For each pre‐pregnancy BMI, the weight gains during pregnancy that minimized the predicted probability of various adverse perinatal events were 12–15, 10–13, 7–10, and upper limit of 5 kg for the underweight, normal‐weight, obese 1, and obese ≥2 groups, respectively. Conclusions: The weight gain during pregnancy that minimizes the predicted probability of various perinatal adverse events according to the pre‐pregnancy BMI was established. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer.

Author

Nakamura, Keiichiro, Matsuoka, Hirofumi, Yorimitsu, Masae, Ogawa, Mariko, Kanemori, Miho, Sueoka, Kotaro, Kozai, Ayumi, Nakamura, Hiroko, Haruma, Tomoko, Shiroyama, Yuko, Hayata, Yuu, Sugii, Hirokazu, Ueda, Akiko, Kurihara, Shuichi, Urayama, Saiko, Shimizu, Miyuki, and Masuyama, Hisashi

Published
2024
Full Text
View/download PDF

44. Liquid Biopsy Revealed HBOC Pedigree and Led to Medical Management Among the Relatives

Author

Ogawa, Chikako, Hirasawa, Akira, Sogawa, Reimi, Hasuoka, Kayoko, Tomida, Shuta, Futagawa, Mashu, Urakawa, Yusaku, Kochi, Mariko, Yamamoto, Hideki, Nakamura, Keiichiro, and Masuyama, Hisashi

Subjects
hereditary breast and ovarian cancer (HBOC), BRCA 1, germline findings, presumed germline pathogenic variants (PGPV), cancer precision medicine
Abstract

A hereditary breast and ovarian cancer (HBOC) pedigree was detected via liquid biopsy, and cancer prevention was initiated for the patient’s daughter, after receiving a definitive result from BRCA genetic testing. A 48-yearold woman with ovarian cancer was administered precision medicine, which used cell-free DNA from plasma. The results revealed a pathogenic variant of BRCA1 as a presumed germline pathogenic mutation. We confirmed the germline pathological variant BRCA1 c.81-1G> A and suggested treatment with a PARP inhibitor. One of her three children had the variant, was diagnosed as an unaffected pathogenic variant carrier, and was advised to initiate surveillance.

Published
2022

46. Short stature in small-for-gestational-age offspring born to mothers with hypertensive disorders of pregnancy

Author

Mishima, Sakurako, Mitsui, Takashi, Tani, Kazumasa, Maki, Jota, Eto, Eriko, Hayata, Kei, Washio, Yosuke, Yoshimoto, Junko, Tsukahara, Hirokazu, Masuyama, Hisashi, Mishima, Sakurako, Mitsui, Takashi, Tani, Kazumasa, Maki, Jota, Eto, Eriko, Hayata, Kei, Washio, Yosuke, Yoshimoto, Junko, Tsukahara, Hirokazu, and Masuyama, Hisashi

Abstract

Objective: To investigate the incidence and risk factors of small-for-gestational age (SGA) short stature at 2 and 3 years of age in SGA offspring born to women with hypertensive disorders of pregnancy (HDP). Methods: We examined 226 women with HDP whose respective SGA offspring were delivered. Results: Eighty offspring (41.2%) were diagnosed with SGA short stature. The prematurity before 32 weeks of gestation was the most significant factor for catch-up growth failure. Conclusion: In SGA offspring born to women with HDP, SGA short stature incidence was high, and the risk factor was prematurity before 32 weeks of gestation.

Published
2023

49. Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia

Author

Bian, Xuming, Biswas, Arijit, Huang, Xianghuang, Lee, Kyoung Jin, Li, Thomas Kwok-To, Masuyama, Hisashi, Ohkuchi, Akihide, Park, Joong Shin, Saito, Shigeru, Tan, Kok Hian, Yamamoto, Tatsuo, Dietl, Angela, Grill, Sonja, Verhagen-Kamerbeek, Wilma D.J., Shim, Jae-Yoon, and Hund, Martin

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results